Navigation Links
Duska Therapeutics Completes Corporate Name Change to Cordex Pharma

Stock to trade under new ticker symbol 'CDXP.OB'

LA JOLLA, Calif., Jan. 28 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) announced today that it has completed a corporate name change to Cordex Pharma, Inc. As a result of the name change, the Over-the-Counter Bulletin Board will trade the Company's common stock under the ticker symbol OTCBB: CDXP.OB.

James S. Kuo, M.D., Cordex's Chief Executive Officer commented, "We are pleased to have completed our corporate name change and selected a new ticker symbol. The Cordex name was chosen for two primary reasons. First, 'cor' is the Latin word for heart, which is the focus of our drug development efforts. Second, Cordex is an intentional derivation of 'codex', the Latin word for book. Before printing presses, handwritten codices were the repository of all human knowledge. Through our two late-stage clinical programs, we intend to write a new chapter in the development of proprietary pharmaceuticals that treat urgent medical needs."

In addition to the name change and new ticker symbol, Cordex announced several other corporate changes. The Company has appointed MorisonCogen, LP of Bala Cynwyd, PA, as its independent auditors for the year ending December 31, 2008. Cordex also appointed DirectTransfer, LLC as its stock transfer agent, effective immediately.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex is developing a portfolio of investigational medicines, two of which are in late stages of clinical trials. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia early in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure early in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure and our intent to write a new chapter in the development of proprietary pharmaceuticals that treat urgent medical needs. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.

SOURCE Duska Therapeutics, Inc.; Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
8. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
9. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
10. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
11. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Post Your Comments:
(Date:10/13/2015)... Calif. , Oct. 13, 2015  Asterias ... agreement with the UK-based Cell Therapy Catapult to ... AST-VAC2, Asterias, allogeneic dendritic cell immunotherapy. Under the ... scale manufacturing processes for AST-VAC2 to support advanced ... --> --> The ...
(Date:10/12/2015)... Apheresis is an invasive process that involves the ... components from whole blood. In this procedure, the blood of ... machine or a blood cell separator. The apheresis equipment spins ... components. A selected part of the blood is removed, and ... patient. It involves the use of devices and disposables along ...
(Date:10/12/2015)... 12, 2015  The Pharmacy Compounding Accreditation Board ... Pharmacy in Costa Mesa , ... the pharmacy,s commitment to meeting and/or exceeding national ... --> --> ... --> --> Harbor Compounding ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... According to an article published October 5th ... who successfully lose weight with a bariatric procedure are much less likely to develop ... notes that anywhere from 40 to 50 percent of all endometrial cancer cases are ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Symposium Chairman, Dr. ... 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. The ... afterwards, draws plastic surgeons and cosmetic physicians from around the world. , Key topics ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... unique private messaging application, announced today a significant contract that will provide its ... Independence plans to build on the growing success of its Relay program, IBX ...
(Date:10/13/2015)... ... ... NavaFit Inc. today announced the launch of its NavaFit app for iPhone® ... fitness & sporting events, and stay motivated. Users can download the apps ... to get more serious about fitness and wellness, individuals are constantly looking for new ...
(Date:10/13/2015)... ... 2015 , ... Protein is essential to good health. You need it to ... how much protein does the average man need in order to stay healthy? ... 2015 issue of Harvard Men's Health Watch . Most Americans get about 15% ...
Breaking Medicine News(10 mins):